Skip to results

Area of interest

Area of interest

Type (2 selected)

Type

Guidance programme

Showing 1 to 345 of 345

Guidance and quality standards awaiting development
TitleType
10395 - Aprocitentan for treating resistant hypertension TS ID 10395Technology appraisal guidance
Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095Technology appraisal guidance
Abdominal aortic aneurysmQuality standard
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]Technology appraisal guidance
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]Technology appraisal guidance
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]Technology appraisal guidance
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]Technology appraisal guidance
Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma TS ID 11823Technology appraisal guidance
AcneQuality standard
Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy [ID6354]Technology appraisal guidance
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6339]Technology appraisal guidance
Adalimumab for treating early Dupuytren's contracture TS ID 11870Technology appraisal guidance
Adrenal dysfunctionQuality standard
Adults with lifelong or very severe hearing or visual impairment: health, well-being and social careQuality standard
Advocacy services for adults with health and social care needsQuality standard
Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]Technology appraisal guidance
AI-supported colorectal polyp detectionHealth technology evaluation
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over TS ID 10680Technology appraisal guidance
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments TS ID 11830Technology appraisal guidance
Ambulatory pulmonary artery pressure monitoring devicesDiagnostics guidance
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]Technology appraisal guidance
Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]Technology appraisal guidance
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer TS ID 11967Technology appraisal guidance
Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasiaMedical technologies guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer ID 6200Technology appraisal guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]Technology appraisal guidance
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]Technology appraisal guidance
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]Technology appraisal guidance
Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]Technology appraisal guidance
Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer TSID 10710Technology appraisal guidance
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]Technology appraisal guidance
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]Technology appraisal guidance
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]Technology appraisal guidance
Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]Technology appraisal guidance
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769Technology appraisal guidance
Benralizumab for previously treated severe nasal polyps [ID1659]Technology appraisal guidance
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over TS ID 11867Technology appraisal guidance
Benralizumab with corticosteroids for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis [ID6266]Technology appraisal guidance
Bentracimab for reversing the antiplatelet activity of ticagrelor TS ID 10550Technology appraisal guidance
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]Technology appraisal guidance
BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]Technology appraisal guidance
BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]Technology appraisal guidance
Bimekizumab for treating ankylosing spondylitis TS ID 10334Technology appraisal guidance
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease TS ID 11991Technology appraisal guidance
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa TS ID 10592Technology appraisal guidance
Botulinum toxin type A for preventing episodic migraine ID 6450Technology appraisal guidance
Brensocatib for treating moderate to severe non-cystic fibrosis bronchiectasis in people 12 years and over ID 6448Technology appraisal guidance
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]Technology appraisal guidance
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma ID 6437Technology appraisal guidance
Bupivacaine–meloxicam for treating postoperative pain [ID2728]Technology appraisal guidance
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]Technology appraisal guidance
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]Technology appraisal guidance
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]Technology appraisal guidance
CAEL-101 with standard care for untreated amyloid light chain amyloidosis TS ID 10666Technology appraisal guidance
Canagliflozin for treating type 2 diabetes in people 10 to 17 years TS ID 11888Technology appraisal guidance
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]Technology appraisal guidance
Caval valve implantation for tricuspid regurgitationInterventional procedures guidance
Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy TS ID 10214Technology appraisal guidance
Children and young people with disabilities and severe complex needs: integrated health and social care supportQuality standard
Compression products for wound careHealth technology evaluation
Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]Technology appraisal guidance
Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitisInterventional procedures guidance
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)Technology appraisal guidance
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 TS ID 11839Technology appraisal guidance
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over TS ID 11838Technology appraisal guidance
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]Technology appraisal guidance
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable ID6249Technology appraisal guidance
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TSID 12045Technology appraisal guidance
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]Technology appraisal guidance
Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy TS ID 11840Technology appraisal guidance
Delgocitinib for treating moderate to severe chronic hand eczema ID6408Technology appraisal guidance
Depemokimab for treating chronic rhinosinusitis with nasal polyps ID 6449Technology appraisal guidance
Depemokimab for treating severe eosinophilic asthma in people 12 years and over TSID 12017Technology appraisal guidance
Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over TS ID 10392Technology appraisal guidance
Deucravacitinib for treating active psoriatic arthritis TS ID 11981Technology appraisal guidance
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154Technology appraisal guidance
Digital front door for people accessing NHS Talking TherapiesDiagnostics guidance
Digital platforms for community based self-management of mild to moderate osteoarthritis and joint painMedical technologies guidance
Digital platforms to support cardiac rehabilitationMedical technologies guidance
Diverticular diseaseQuality standard
Dostarlimab with carboplatin and paclitaxel for untreated recurrent or advanced endometrial cancer with high microsatellite stability or mismatch repair proficiency ID6415Technology appraisal guidance
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]Technology appraisal guidance
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]Technology appraisal guidance
Dulaglutide for treating type 2 diabetes [ID1451]Technology appraisal guidance
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years TS ID 11885Technology appraisal guidance
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736Technology appraisal guidance
Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]Technology appraisal guidance
Durvalumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6168]Technology appraisal guidance
Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5073]Technology appraisal guidance
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]Technology appraisal guidance
Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]Technology appraisal guidance
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID 5080]Technology appraisal guidance
Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]Technology appraisal guidance
Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6146Technology appraisal guidance
Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]Technology appraisal guidance
Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer (Review of TA662) [ID6404]Technology appraisal guidance
Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]Technology appraisal guidance
Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]Technology appraisal guidance
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]Technology appraisal guidance
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID 5097]Technology appraisal guidance
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]Technology appraisal guidance
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]Technology appraisal guidance
Edaravone for treating amyotrophic lateral sclerosis TS ID 11869Technology appraisal guidance
Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide TS ID 10046Technology appraisal guidance
Electrically stimulated intravesical therapy for Interstitial CystitisInterventional procedures guidance
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over TS ID 11847Technology appraisal guidance
Elinzanetant for treating vasomotor symptoms associated with menopause TS ID 11917Technology appraisal guidance
Endoscopic bipolar radiofrequency ablation for malignant biliary obstructionInterventional procedures guidance
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer TS ID 10718Technology appraisal guidance
Ensitrelvir for treating COVID 19 [ID6231]Technology appraisal guidance
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy TSID 12015Technology appraisal guidance
Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 ID4037Technology appraisal guidance
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]Technology appraisal guidance
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806Technology appraisal guidance
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920Technology appraisal guidance
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]Technology appraisal guidance
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]Technology appraisal guidance
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]Technology appraisal guidance
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]Technology appraisal guidance
Galcanezumab for migraine TS ID 10663Technology appraisal guidance
GamblingQuality standard
Gantenerumab for treating early Alzheimer's disease TS ID 10668Technology appraisal guidance
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over ID6394Technology appraisal guidance
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]Technology appraisal guidance
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A TS ID 9772Technology appraisal guidance
Gosuranemab for treating progressive supranuclear palsy [ID1607]Technology appraisal guidance
GoutQuality standard
Heart valve disease in adultsQuality standard
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]Technology appraisal guidance
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]Technology appraisal guidance
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]Technology appraisal guidance
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies TS ID 10330Technology appraisal guidance
In-situ Normothermic Regional Perfusion system for DCD donorsInterventional procedures guidance
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer TS ID 11990Technology appraisal guidance
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430Technology appraisal guidance
Infant, children and young people's experience of health careQuality standard
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]Technology appraisal guidance
Insertion of a Catheter based intravascular microaxial blood pump for acute heart failureInterventional procedures guidance
Intravascular lithotripsy for calcified coronary arteries during percutaneous coronary interventionInterventional procedures guidance
Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset TS ID 10190Technology appraisal guidance
Iptacopan for treating complement 3 glomerulopathy TS ID 10435Technology appraisal guidance
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949Technology appraisal guidance
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]Technology appraisal guidance
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]Technology appraisal guidance
Laparoscopic insertion of a non-active implant for gastro-oesophageal reflux diseaseInterventional procedures guidance
Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]Technology appraisal guidance
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822Technology appraisal guidance
Leadless cardiac pacemaker implantation for bradyarrhythmiasInterventional procedures guidance
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]Technology appraisal guidance
Leriglitazone for treating X-linked andrenoleukodystrophy TS ID 9996Technology appraisal guidance
Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant TS ID 11868Technology appraisal guidance
Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults TS ID 10652Technology appraisal guidance
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer TS ID 10203Technology appraisal guidance
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]Technology appraisal guidance
Linerixibat for treating pruritus in people with primary biliary cholangitis TS ID 10136Technology appraisal guidance
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]Technology appraisal guidance
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer TS ID 11970Technology appraisal guidance
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]Technology appraisal guidance
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]Technology appraisal guidance
Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]Technology appraisal guidance
Managing symptoms with an uncertain causeQuality standard
Masitinib with riluzole for treating amyotrophic lateral sclerosis TS ID 10728Technology appraisal guidance
Mavorixafor for treating WHIM syndrome ID3946Technology appraisal guidance
Mepolizumab for treating chronic obstructive pulmonary disease [ID1237]Technology appraisal guidance
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400Technology appraisal guidance
Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 TS ID 10730Technology appraisal guidance
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442Technology appraisal guidance
MRI guided focused ultrasound subthalamotomy in parkinson's diseaseInterventional procedures guidance
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]Technology appraisal guidance
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over TS ID 11777Technology appraisal guidance
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]Technology appraisal guidance
Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping TS ID 10593Technology appraisal guidance
Nipocalimab for treating generalised myasthenia gravis TS ID 11958Technology appraisal guidance
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer TSID 12044Technology appraisal guidance
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer TS ID 10523Technology appraisal guidance
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]Technology appraisal guidance
Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]Technology appraisal guidance
Nirogacestat for treating desmoid tumours TSID 12039Technology appraisal guidance
Nitazoxanide for treating the common cold in people 12 years and over TS ID 10548Technology appraisal guidance
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]Technology appraisal guidance
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma TS ID 9659Technology appraisal guidance
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]Technology appraisal guidance
Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia ID6347Technology appraisal guidance
Obinutuzumab for treating lupus nephritis TID6420Technology appraisal guidance
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy TSID 11996Technology appraisal guidance
Omaveloxolone for treating Friedreich's ataxia in people aged 16 to 40 ID6423Technology appraisal guidance
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]Technology appraisal guidance
Ondansetron for treating alcohol-use disorder TS ID 11884Technology appraisal guidance
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941Technology appraisal guidance
Oral semaglutide for managing overweight and obesity [ID6188]Technology appraisal guidance
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced or unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]Technology appraisal guidance
OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]Highly specialised technology
Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]Technology appraisal guidance
Pain management (young people and adults)Quality standard
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]Technology appraisal guidance
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]Technology appraisal guidance
Pancreatitis (including acute pancreatitis)Quality standard
Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over TS ID 11865Technology appraisal guidance
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]Technology appraisal guidance
Pelvic floor dysfunctionQuality standard
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer TSID 12021Technology appraisal guidance
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]Technology appraisal guidance
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer TS ID 10690Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer TS ID 11953Technology appraisal guidance
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer ID 6399Technology appraisal guidance
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer TS ID 11852Technology appraisal guidance
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent TS ID 11808Technology appraisal guidance
Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]Technology appraisal guidance
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]Technology appraisal guidance
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]Technology appraisal guidance
Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TS ID 11810Technology appraisal guidance
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer TS ID 11861Technology appraisal guidance
Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]Technology appraisal guidance
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage ID6412 small-cell lung cancer TS ID 11975Technology appraisal guidance
Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]Technology appraisal guidance
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]Technology appraisal guidance
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587Technology appraisal guidance
Perioperative careQuality standard
Pernicious anaemiaQuality standard
Phrenic nerve pacing for congenital central hypoventilation syndromeInterventional procedures guidance
Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injuryInterventional procedures guidance
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]Technology appraisal guidance
PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989]Technology appraisal guidance
Prevention of dementiaQuality standard
Primary hyperparathyroidismQuality standard
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]Technology appraisal guidance
Pulsed Field Ablation (PFA) for atrial fibrillationInterventional procedures guidance
PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over TS ID 9130Technology appraisal guidance
Ranibizumab port delivery system for treating diabetic macular oedema TS ID 10549Technology appraisal guidance
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over TS ID 10642Technology appraisal guidance
Readmission to ICU within 48hrsQuality standard
REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443Technology appraisal guidance
Remdesivir for treating COVID 19 [ID3808]Technology appraisal guidance
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines TS ID 11903Technology appraisal guidance
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis TS ID 11905Technology appraisal guidance
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436Technology appraisal guidance
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]Technology appraisal guidance
Rivaroxaban for treating chronic heart failure [ID1462]Technology appraisal guidance
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]Technology appraisal guidance
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764Technology appraisal guidance
Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy TS ID 10763Technology appraisal guidance
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]Technology appraisal guidance
Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]Technology appraisal guidance
Sabizabulin for treating COVID 19 TS ID 11814Technology appraisal guidance
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]Technology appraisal guidance
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433Technology appraisal guidance
Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawalQuality standard
Safeguarding adults in care homesQuality standard
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years TS ID 10237Technology appraisal guidance
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]Technology appraisal guidance
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over TS ID 11846Technology appraisal guidance
Secondary care management of malignant hypertensionQuality standard
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]Technology appraisal guidance
Selpercatinib for treating advanced thyroid cancer with RET alterations (MA review of TA742) [ID6288]Technology appraisal guidance
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options TS ID 11850Technology appraisal guidance
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441Technology appraisal guidance
Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis TS ID 11945Technology appraisal guidance
Semaglutide for treating type 2 diabetes (ID1450)Technology appraisal guidance
Serplulimab with chemotherapy for untreated extensive-stage small-cell lung cancer [ID6346]Technology appraisal guidance
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995Technology appraisal guidance
Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 TS ID 11827Technology appraisal guidance
Shared decision-making: practical guidance for health and social care professionalsQuality standard
Single-step scaffold insertion for repairing symptomatic chondral knee defectsInterventional procedures guidance
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease TS ID 9147Technology appraisal guidance
Sleep disordered breathingQuality standard
Social work interventions for adults with complex needs (including learning disabilities) and mental health needsQuality standard
Sodium zirconium cyclosilicate for the first line treatment of hyperkalaemia [ID6439]Technology appraisal guidance
Sotagliflozin for treating type 2 diabetes [ID1657]Technology appraisal guidance
Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]Technology appraisal guidance
Speedboat Inject for endoscopic submucosal dissection of lower gastrointestinal lesionsMedical technologies guidance
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]Technology appraisal guidance
STS101 for treating acute migraine TS ID 11782Technology appraisal guidance
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy ID6409Technology appraisal guidance
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia TS ID 11977Technology appraisal guidance
Supporting independent living and preventing isolation in adults of working age with social care needsQuality standard
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments ID6413Technology appraisal guidance
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation TSID 12009Technology appraisal guidance
Talquetamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID 5082]Technology appraisal guidance
Targeted Muscle Reinnervation for refractory pain after limb amputationInterventional procedures guidance
Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]Technology appraisal guidance
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]Technology appraisal guidance
Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition [ID6259]Technology appraisal guidance
Teprotumumab for treating thyroid eye disease ID 6432Technology appraisal guidance
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps TS ID 11918Technology appraisal guidance
The Sonata Treatment - Transcervical Radiofrequency Fibroid Ablation using Intrauterine UltrasoundMedical technologies guidance
Thyroid diseaseQuality standard
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915 ]Technology appraisal guidance
Timrepigene emparvovec for treating choroideremia [ID3916]Technology appraisal guidance
TinnitusQuality standard
Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer TS ID 11951Technology appraisal guidance
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]Technology appraisal guidance
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]Technology appraisal guidance
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]Technology appraisal guidance
Tiratricol for treating Allan–Herndon–Dudley syndrome TS ID 11794Technology appraisal guidance
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161]Technology appraisal guidance
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683Technology appraisal guidance
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162]Technology appraisal guidance
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]Technology appraisal guidance
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]Technology appraisal guidance
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]Technology appraisal guidance
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]Technology appraisal guidance
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]Technology appraisal guidance
Tocilizumab for treating systemic sclerosis (ID1396)Technology appraisal guidance
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]Technology appraisal guidance
Tolebrutinib for treating relapsing multiple sclerosis TS ID 11845Technology appraisal guidance
Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous systemic chemotherapy [ID6414]Technology appraisal guidance
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]Technology appraisal guidance
Transcatheter aortic valve implantation for aortic incompetenceInterventional procedures guidance
Transperineal laser ablation (TPLA) for treating lower urinary tract symptoms of benign prostatic hyperplasia using a ultra-micro invasive approach.Interventional procedures guidance
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer TS ID 11910Technology appraisal guidance
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]Technology appraisal guidance
Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]Technology appraisal guidance
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]Technology appraisal guidance
Treprostinil diethanolamine for treating pulmonary arterial hypertension TS ID 11772Technology appraisal guidance
Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]Technology appraisal guidance
Troriluzole for spinocerebellar ataxia TS ID 12013Technology appraisal guidance
Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]Technology appraisal guidance
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together TS ID 11781Technology appraisal guidance
Unilateral MRI-guided focused ultrasound thalamotomy for moderate-to-severe tremor in Parkinson's diseaseInterventional procedures guidance
Upadacitinib for treating giant cell arteritis [ID6299]Technology appraisal guidance
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]Technology appraisal guidance
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutation in the CFTR gene in people aged 6 years and over TS ID 11919Technology appraisal guidance
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]Technology appraisal guidance
Venglustat for treating gangliosidoses in people 2 years and over [ID6358]Technology appraisal guidance
Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]Technology appraisal guidance
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]Technology appraisal guidance
Vilobelimab for treating COVID 19 TS ID 11815Technology appraisal guidance
Virtual Wards for COPD exacerbationsMedical technologies guidance
Virtual Wards for Heart FailureMedical technologies guidance
Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable TS ID 10266Technology appraisal guidance
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over TS ID 11974Technology appraisal guidance
Vosoritide for treating achondroplasia in children TSID 12001Technology appraisal guidance
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]Technology appraisal guidance
Vulnerable populations: strategies for tackling inequalitiesQuality standard
WP1048 for treating grass pollen allergy in people aged 18 to 60 TS ID 10467Technology appraisal guidance
Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity TS ID 11902Technology appraisal guidance
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable TS ID 10477Technology appraisal guidance
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments TS ID 11952Technology appraisal guidance
Zavegepant for treating acute migraine TSID 11998Technology appraisal guidance
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]Technology appraisal guidance
Zuranolone for treating severe postnatal depression ID6431Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All